CURE-GN: The Cure Glomerulopathy Network (H-35886)

The goal of this study is to enroll and follow 2400 patients with glomerular disease long-term in a prospective registry. Patients are enrolled within five years of their diagnosis with the most common forms of primary glomerular disease: IgA nephropathy (IgAN), IgA vasculitis-glomerulonephritis (IgAV-GN, also known as Henoch Schoenleinpurpura-nephritis), focal segmental glomerulosclerosis (FSGS), minimal change nephrotic syndrome (MCNS), and membranous nephropathy. Blood and urine samples are collected longitudinally over time, in order to integrate proteomics and metaboloic biomarkers with genomic data, pathology data, clinical and patient reported outcome data. Baylor is one of the sites enrolling children for the Midwest Pediatric Nephrology Consortium (MWPNC), and over 30% of enrolled patients in this study were enrolled as children. 

Baylor is also lead site for an ancillary study on a subset of patients with C1q nephropathy. Although C1q nephropathy is considered a subset of either FSGS or MCNS, it is unknown if patients with C1q nephropathy respond to therapy differently than patients with FSGS or MCNS without C1q nephropathy. The genetic, molecular, and pathobiology of C1q nephropathy is unknown, but may differ substantially from other subsets of FSGS and MCNS.